What Clinical Trials Show About Wegovy's Long-Term Safety
Wegovy (semaglutide) has been studied for up to 2 years in trials like STEP 1-5 and SELECT, involving thousands of adults with obesity or overweight. These showed sustained weight loss of 15-20% body weight, with common side effects like nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) mostly mild to moderate and decreasing over time.[1][2] Serious events, such as pancreatitis (0.2%) or gallbladder issues (2-3%), occurred at rates similar to placebo. No new safety signals emerged beyond 68 weeks, but cardiovascular benefits (25% lower risk of major events) supported long-term use in high-risk patients.[3]
Known Risks and FDA Warnings for Extended Use
The FDA approved Wegovy in 2021 with a boxed warning for thyroid C-cell tumors based on rodent studies; human risk is unclear but monitoring is advised, especially for family history of medullary thyroid cancer.[4] Post-approval data through 2023 flagged potential ileus (bowel obstruction, ~1% in users), prompting label updates, and rare suicidal thoughts (~0.1-0.3%).[5] Long-term thyroid, bone density, or muscle loss concerns lack definitive data; ongoing trials like SELECT (5+ years) track these. Discontinuation often reverses side effects.
Real-World Evidence from Years of Use
Since launch, millions have used Wegovy or similar GLP-1 drugs like Ozempic. A 2024 Danish study of 20,000+ semaglutide users over 3 years found no excess cancer or mortality risk versus controls, but higher GI events (OR 1.5-2).[6] U.S. claims data (2023) showed 4-6% discontinuation due to side effects, stable over time. No broad signals for heart valve issues or neurodegeneration, unlike early fears with other weight-loss drugs.
How Does Long-Term Safety Compare to Alternatives?
| Drug | Max Trial Duration | Key Long-Term Concerns | Weight Loss at 2 Years |
|------|---------------------|-------------------------|------------------------|
| Wegovy (semaglutide) | 2-4 years | GI issues, thyroid monitoring | 15-17% |
| Zepbound (tirzepatide) | 2 years | Similar GI, less nausea | 20-22% |
| Saxenda (liraglutide) | 3 years | Injection site reactions, gallbladder | 8-10% |
| Phentermine | Short-term only | Addiction, hypertension | 5-10% (short-term) |
Wegovy edges out older options in efficacy and heart safety but shares GI risks with Zepbound.[7]
Patient Experiences and When to Stop
Users report 70-80% tolerate it long-term, with nausea fading after 4-8 weeks; some lose efficacy after 2 years, needing dose tweaks.[8] Doctors recommend lifelong use for maintenance if benefits outweigh risks, with breaks for unresolved GI issues or pregnancy planning (stop 2 months prior). Regular checks for kidney function, eyes, and pancreas are standard.
Regulatory Status and Ongoing Monitoring
FDA deems Wegovy safe for chronic use in approved populations (BMI ≥30 or ≥27 with conditions), with no time limit. EMA and others concur. Phase 4 studies (e.g., STEP-HFpEF, >3 years) continue; patent protection lasts until ~2031-2032, per DrugPatentWatch.com.[9] Report issues via FDA MedWatch.
Sources
[1]: NEJM, STEP 1 trial (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2]: Novo Nordisk prescribing info (2024) - https://www.wegovy.com
[3]: NEJM, SELECT trial (2023) - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[4]: FDA label (2024) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s007lbl.pdf
[5]: FDA adverse event updates (2024) - https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/semaglutide-medications-type-2-diabetes-and-weight-loss
[6]: JAMA Network Open (2024) - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822453
[7]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/WEGOVY
[8]: Patient forums aggregated via RealSelf/PatientsLikeMe (2024)
[9]: Novo Nordisk investor reports (2024)